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A follow-up study of 1844 renal transplant patients in Italy showed a 113-fold increased risk for Kaposi’s sarcoma. Kaposi’s sarcoma
risk was higher in persons born in southern than in northern Italy. Significant increases were also observed for cancers of the lip, liver,
kidney and for non-Hodgkin’s lymphoma.
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Renal transplant patients experience higher rates of cancer,
particularly virus-related cancers, than the general population.
The overall cancer risk is three- to four-fold elevated, but some
specific cancers show greater increases (Kinlen, 1992). For
nonmelanoma skin cancers and lip cancer, the relative risks are
increased 10- to 60-fold (Kinlen et al, 1979; Birkeland et al, 1995;
Adami et al, 2003), while the excess of non-Hodgkin’s lymphoma
(NHL) is about five- to 10-fold (Hoshida et al, 1997; Birkeland et al,
2000; Adami et al, 2003). Kaposi’s sarcoma (KS) has been frequently
reported in transplant patients in the United States (Penn, 2000), in
the Middle East (Qunibi et al, 1988) and in Italy (Montagnino et al,
1996; Pedotti et al, 2003), but the excess risk has not been closely
quantified. No increased risk of KS has been reported in transplant
patients from the Nordic countries (Birkeland et al, 1995, 2000;
Adami et al, 2003), or Japan (Hoshida et al, 1997).
The prevalence of infection with KS-associated herpesvirus (i.e.,
human Herpesvirus type 8 (HHV-8)) (Whitby et al, 1998; Serraino
et al, 2000; Vitale et al, 2001) and the incidence of classic KS
(Franceschi and Geddes, 1995; Dal Maso et al, 2004) are relatively
high in Italy, particularly in the South. The aim of this study was to
quantify the excess of KS risk, to identify factors associated with
KS occurrence, and also to define the spectrum of cancers
associated with immunosuppression in patients from two major
Italian transplant centres.
MATERIALS AND METHODS
Anonymous information was collected on 1844 patients resident in
different parts of Italy and transplanted in northern (Milan) or
central Italy (Rome). Of these, 1340 received their transplants at
Niguarda Hospital, Milan, between 1972 and 2003 and 504 at
Policlinico Gemelli Hospital, Rome, between 1970 and 2000. As
with other investigations, we excluded patients who survived less
than 10 days after transplant, those with a pretransplant history of
cancer, or who developed cancer in the 30-day period after
transplantation (Adami et al, 2003; Pedotti et al, 2003).
Nonmelanoma skin cancers were not evaluated since information
on basal cell carcinoma was not recorded and that on squamous
cell carcinoma might not have been complete.
Person-years (PY) at cancer risk were measured from the date of
first renal transplant and ended upon at tumour diagnosis, death,
or date of last follow-up visit, whichever occurred first. For the
purposes of this analysis, periods of graft failure were not
considered. For each type of cancer observed, the expected
number (standardised for sex, age, and area of residence) was
computed using incidence rates from all population-based cancer
registries of Italy for the 1988–1992 period (Parkin et al, 1997).
Standardised incidence ratios (SIRs) were computed for all cancers
with at least two observed cases, and were obtained by dividing the
number of observed cases by the number of expected cases.
Ninety-five percent confidence intervals (CI) of SIRs were
determined using the Poisson distribution (Breslow and Day,
1980). Incidence rate ratios (IRRs) and their 95% CIs, adjusted for
sex, age, area of birth, and time since transplant, were computed to
assess the association between selected characteristics and KS risk
among transplant patients.
RESULTS
The median age of the 1844 renal transplant patients was 42 years
(interquartile range: 31–51 years). In 15940 PY of observation
(median follow-up time: 7.0 years), 104 cases of cancer, other than
nonmelanoma skin cancers, were diagnosed. Standardised incidence
ratios according to cancer type or site, and sex are shown in Table 1.
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similar magnitude in the two sexes. The SIR for KS was 112.6 but it
was greater among women (SIR¼451, 95% CI: 147–1053) than
men (SIR¼93, 95% CI: 55–147). A 6.6-fold increased SIR (95% CI:
3.7–11.0) was seen for NHL. Other cancers with significantly
elevated SIRs included: carcinomas of the lip (SIR¼14.6; 95% CI:
1.8–52.7), liver (SIR¼3.9; 95% CI: 1.5–8.6), and kidney
(SIR¼3.9; 95% CI: 1.6–8.0). The SIRs for lip and liver cancers
were more elevated in women than men, whereas the excess risk
for native renal cancer was found in men only (Table 1).
Standardised incidence ratios for stomach (SIR¼1.2), colon
(SIR¼1.0), lung (SIR¼0.8), and female breast cancers (SIR¼0.7)
0.7) were close to unity (Table 1).
Among renal transplant patients, KS was more frequent
(IRR¼3.0, 95% CI: 1.1–8.5) in persons aged 50 years or older at
transplant than in those younger than 40. Kaposi’s sarcoma was
nonsignificantly more common in men than in women, whereas it
was nearly six-fold more frequent (95% CI: 1.6–19.7) in patients
born in southern Italy, as compared to those born in northern Italy
(Table 2). A strong inverse association emerged between KS
occurrence and time since renal transplant. In the first year
following transplant, KS was 4.5-fold more frequent (95% CI: 1.6–
12.2) than after 4 or more years (Table 2).
Most of these 1844 patients (87%) received their transplant after
cyclosporin came into widespread use (from 1983 onwards), and
one-third after the introduction of the newer immunosuppressive
drugs (from 1997 onwards). All 23 KS cases were diagnosed in
1983 or later inpatients who were treated with cyclosporin-
containing regimens. No significant difference in KS IRRs was seen
according to the calendar period of transplant (Table 2).
DISCUSSION
Our study provides estimates of cancer incidence for renal
transplant recipients in northern or central Italy and IRRs for
KS. The overall increase in cancer risk we found (1.8-fold) is
somewhat lower than that reported from previous investigations in
transplant patients (Kinlen et al, 1979; Birkeland et al, 1995;
Hoshida et al, 1997; Adami et al, 2003), but the exclusion in our
analysis of nonmelanoma skin cancers explains a large part of this
difference.
With respect to the increased risks for NHL and renal cancer,
our results agree with previous investigations (Kinlen, 1992;
Birkeland et al, 1995; Adami et al, 2003). It is noteworthy that all
cases of renal cancer in this study involved the native kidney, a
distinction not mentioned in previous studies. The quantified high
risk of KS, particularly in women, and the peak in KS risk in the
first year following transplant are new findings. The short
induction period between transplant and KS diagnosis suggests
that KS development in transplant patients is associated with a
rapid re-activation of latent HHV-8 infection (Andreoni et al, 2001;
Cannon et al, 2003). The investigation of geographical factors
confirmed a higher (about six-fold) KS risk for individuals born in
the South of Italy, as compared to those born in the North (Geddes
et al, 1995; Dal Maso et al, 2004). On account of massive South-to-
North migration in Italy in the last decades, 44.3% of our study
patients born in the South lived in the North at time of transplant.
The KS incidence rate among renal transplant recipients born and
resident in the South (i.e., 24.16 per 10000 PY) was about five-fold
higher than that among those born and resident in the North (i.e.,
4.62 per 10000 PY) (data not shown in tables). Moreover, KS
incidence among patients who were born in the South, but lived in
the North, was similar to that of patients who were born and
resident in the South (i.e., 24.70 per 10000 PY). Information on age
at migration was not available in this study, but the stronger
association of KS with place of birth than with area of living
suggests that acquisition of HHV-8 occurs early in life.
This study also revealed that renal transplant patients in Italy
have a four-fold increased risk of liver cancer, an excess risk not
generally seen in transplant patients elsewhere (Kinlen, 1992;
Birkeland et al, 1995; Adami et al, 2003). In Italy, mortality rates
for liver cancer (La Vecchia et al, 2000) and the prevalence of
infection with hepatitis B virus and/or with hepatitis C virus
Table 1 Standardised incidence ratio (SIR) of cancer and corresponding 95% confidence interval (CI) after renal transplantation, according to cancer site
or type and sex (Italy, 1970–2003)
Total Men Women
Cancer site/type (ICD-9) Obs SIR 95% CI SIR 95% CI SIR 95% CI
Lip (140) 2 14.6 1.8–52.7 7.8 0.2–43.3 118.0 3.0–658
Stomach (151) 4 1.2 0.3–3.0 1.1 0.2–3.2 1.5 0.0–8.2
Colon (153) 4 1.0 0.3–2.5 0.7 0.1–2.6 1.6 0.2–5.9
Liver (155) 6 3.9 1.5–8.6 2.3 0.5–6.6 15.6 3.2–45.6
Pancreas (157) 2 1.6 0.2–5.6 2.0 0.3–7.3 NC —
Larynx (161) 2 1.0 0.1–3.7 1.1 0.1–3.8 NC —
Lung (162) 8 0.8 0.4–1.6 0.8 0.3–1.6 1.2 0.0–6.9
Melanoma (172) 2 1.4 0.2–5.0 1.1 0.0–6.1 1.9 0.1–10.6
Kaposi’s sarcoma (KAP) 23 112.6 71.4–169 93.2 55.3–147 451.2 147–1053
Bladder (188) 3 0.7 0.1–2.0 0.5 0.1–1.8 2.9 0.1–15.9
Kidney (189) 7 3.9 1.6–8.0 4.8 1.9–9.9 NC —
Thyroid (194) 2 2.4 0.3–8.5 5.8 0.7–20.8 NC —
Non-Hodgkin’s lymphoma (200+202) 15 6.6 3.7–11.0 6.1 3.0–11.2 8.1 2.6–18.8
Multiple myeloma (203) 2 3.8 0.5–13.7 2.6 0.1–14.5 6.9 0.2–38.2
Breast, female (174) 5 — — — — 0.7 0.2–1.7
Cervix uteri (180) 2 — — — — 2.8 0.3–10.1
Corpus uteri (182) 5 — — — — 4.8 1.6–11.2
Ovary (183) 2 — — — — 2.5 0.3–9.2
All cancers but skin
a 99 1.8 1.5–2.2 1.8 1.4–2.3 1.8 1.2–2.6
Obs¼observed number of cancers. NC¼The SIR was not computed because no cancer cases were observed.
aIt includes 99 persons with one or more cancer diagnoses (one
person had three primary cancers and three persons had two primary cancers). It also includes one case each for: brain, mesothelium, nose or middle ear, prostate, small
intestine, testis (seminoma), tonsil and myeloid leukaemia, for a total of 104 cancer diagnoses.
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2004). The higher SIR for liver cancer found in our study than
elsewhere may also be related to the fact that infection with
hepatitis C virus in the recipient is not generally considered a
contraindication for renal transplant in Italy.
In conclusion, our findings in patients who underwent renal
transplantation in northern or central Italy provide further
evidence of the strong association between organ transplant and
virus-related cancers. Our observations on post-transplant KS
confirm the need for HHV-8 screening protocols and for guide-
lines on the clinical management of HHV-8 infection in transplant
centres, at least in areas endemic for KS (Serraino et al, 2005).
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